Fluoroquinolone News and Research

RSS
Fluoroquinolone is a type of drug used to prevent and treat infections. Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture. This risk is further increased in those over age 60, in kidney, heart, and lung transplant recipients, and with use of concomitant steroid therapy.
Drug-resistant tuberculosis levels described as alarming by international study

Drug-resistant tuberculosis levels described as alarming by international study

One-week ciprofloxacin effective for pyelonephritis

One-week ciprofloxacin effective for pyelonephritis

Poultry producers still use FDA-banned antibiotics

Poultry producers still use FDA-banned antibiotics

Oral fluoroquinolones increase risk of retinal detachment

Oral fluoroquinolones increase risk of retinal detachment

Researchers call for collective effort to halt increases in drug-resistant gonorrhea

Researchers call for collective effort to halt increases in drug-resistant gonorrhea

Cefpodoxime not effective in treating uncomplicated cystitis in women

Cefpodoxime not effective in treating uncomplicated cystitis in women

Two-drug combination may alleviate radiation sickness in people

Two-drug combination may alleviate radiation sickness in people

NIAID's ACTG and TB Alliance partner to complete moxifloxacin Phase III trial

NIAID's ACTG and TB Alliance partner to complete moxifloxacin Phase III trial

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Antibiotic-resistant Salmonella worries experts

Antibiotic-resistant Salmonella worries experts

Optimer introduces DIFICID for treatment of C. difficile-associated diarrhea

Optimer introduces DIFICID for treatment of C. difficile-associated diarrhea

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Furiex Pharmaceuticals to present two JNJ-Q2 antibiotic abstracts at ECCMID/ ICC congress

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer reports grant of inducement stock options

Optimer reports grant of inducement stock options